Citi lowered the firm’s price target on Moderna (MRNA) to $28 from $30 and keeps a Neutral rating on the shares. The company announced its Phase 3 CMVictory study of the mRNA-1647 vaccine candidate for cytomegalovirus did not achieve its primary efficacy endpoint, the analyst tells investors in a research note. The firm views the news as disappointed but expects it to have a limited impact on Moderna.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MRNA: